Raj Neervannan co founded AlphaSense raises $100 mn, bullish on India
Darpan News Desk IANS, 12 Apr, 2023 05:20 PM
New Delhi, April 12 (IANS) Market intelligence and search platform AlphaSense, co-founded by Indian-origin Raj Neervannan, on Wednesday said it has raised $100 million in addition to its $225 million Series D financing round at a $1.8 billion valuation through new investments led by CapitalG, Alphabet's independent growth fund.
Existing investors, including the Growth Equity business within Goldman Sachs Asset Management (Goldman Sachs) and Viking Global Investors, also participated in the round.
This investment, said the company, will fuel the continued deployment of AlphaSense's advanced AI capabilities, including generative AI that dramatically speeds up the research process for business and financial professionals.
"This investment will enable us to continue our mission of pushing the boundaries of technology and accelerating our research and development efforts in India, a valuable innovation hub," said Neervannan, Alphasense's CTO and Co-founder.
Neervannan has an MBA in finance from The Wharton School in the US, and a BE in computer science from Birla Institute of Technology and Science, Pilani.
Headquartered in New York City, AlphaSense employs over 1,000 people across offices in the US, the UK, Finland, Germany, and India.
"With the support of CapitalG and our existing investors, we are committed to further enhancing our product offerings and driving value for our global customers. This wouldn't be possible without the talent and innovation of our India employees, and I am excited to see this growth continue," he added.
AlphaSense has spent a decade building and refining its AI tech stack and amassing data to continuously train its language models, while also building its vast collection of top-tier, trustworthy business content.
"The AlphaSense platform is really powerful in how it leverages AI to transform and streamline the work of business and finance professionals globally, including investors like ourselves, as well as many happy users at companies like Google, Bank of America, and Merck," said James Luo, Partner at CapitalG.
AlphaSense enables leading corporations and financial institutions to uncover valuable insights they can't find anywhere else and make smarter decisions with confidence and speed.
"With the big leaps we are taking with AI to deliver even more precise data and insights to our customers, I am more excited than ever by our product roadmap and business momentum," said Jack Kokko, CEO and Founder of AlphaSense.
AlphaSense acquired Stream, the world's broadest library of expert interview transcripts, in 2021 and Sentieo, a financial intelligence platform, in 2022.
The go-ahead for the vaccine developed by American drugmaker Pfizer and Germany's BioNTech comes as the virus surges again in the United States and Europe, putting pressure on hospitals and morgues in some places and forcing new rounds of restrictions that have devastated economies.
Announcing the results on Monday, Moderna said it has submitted emergency use authorisation from the US Food and Drug Administration (FDA), to apply for a conditional marketing authorisation with the European Medicines Agency (EMA) and to progress with the rolling reviews, which have already been initiated with international regulatory agencies.
Protest by thousands of farmers from Punjab and Haryana took place in New Delhi over the weekend entering its fifth day Monday as the farmers continue to showcase their displeasure against the Centre's new farm laws.
Monday's delivery of an 18-and-a-half foot tall Fraser fir by horse-drawn carriage signalled the kickoff of the usual array of White House holiday events that will include the annual turkey pardon and Christmas and Hanukkah events.
The results are based on an interim analysis of trials in the U.K. and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca.
The action comes days after Pfizer Inc. and its German partner BioNTech announced that its vaccine appears 95% effective at preventing mild to severe COVID-19 disease in a large, ongoing study.
.jpg "U.K. approves Pfizer coronavirus vaccine for emergency use, this allows England to be one of the 1st countries to begin vaccinating its population")
